Bariatric Surgery vs. GLP-1s for cardiovascular risk

Key Findings

🧠 Semaglutide Protects Mouse Brains After Traumatic Injury

• 60 mice with traumatic brain injuries showed significant cognitive improvements when treated with semaglutide (50 nmol/kg/day) compared to untreated controls

• The drug reduced neuronal cell death by targeting caspase-dependent pathways—the main route through which brain cells die after injury

• Semaglutide also reduced harmful brain inflammation by blocking M1 microglial activation, suggesting multiple protective mechanisms at work

💊 Higher-Income Patients Get Semaglutide While Lower-Income Need It More

• Analysis of 4.5 million Danish adults found semaglutide use increased with income—from 1.3% in the lowest quartile to 3.6% in the highest

• Obesity rates showed the opposite pattern: 26% in the lowest-income group versus 13% in the highest-income group

• The biggest increase in semaglutide use was among high-income women, rising from 1.9% to 4.1% during 2023

⚠️ SGLT-2 Inhibitors Raise Diabetic Ketoacidosis Risk by 40%

• 143,858 patients with chronic kidney disease and type 2 diabetes showed SGLT-2 inhibitors increased hospitalization risk for diabetic ketoacidosis by 40% compared to GLP-1 receptor agonists

• The absolute risk remained low—4.37 versus 3.13 events per 1,000 person-years—but the relative increase was consistent across patient subgroups

• The number needed to harm was 813 patients per 1,000 person-years, meaning the risk affects a small but measurable portion of patients

❤️ Oral Semaglutide Cuts Heart Failure Events by 22% in Diabetics

• 9,650 participants with type 2 diabetes in the SOUL trial showed oral semaglutide reduced heart failure hospitalizations, urgent visits, and cardiovascular death by 22% in those with existing heart failure

• The benefit was strongest in patients with preserved heart function (41% reduction) versus those with reduced heart function (no significant benefit)

• No increase in serious side effects was observed, and the heart benefits occurred alongside the expected cardiovascular protection

🏥 Medicare Could Save $1.76 Billion Under New Semaglutide Pricing

• Updated cost projections using new Medicare negotiated prices show potential savings of $463 million under standard pricing, rising to $1.76 billion under Most Favored Nation pricing at $245 per month

• Previous estimates assumed much higher costs, but recent White House pricing agreements substantially changed the economic equation for Medicare coverage

• With generic entry assumptions, savings could reach $2.63 billion annually across all FDA-approved semaglutide indications

🍽️ Patients on GLP-1 Drugs Show 53% Higher Risk of Residual Stomach Contents

• 390 patients with type 2 diabetes showed those taking GLP-1 receptor agonists had residual gastric content in 53.3% of cases versus 32.1% in matched controls, even after standard fasting

• Patients with diabetic eye or kidney complications faced the highest risk, creating a "double-hit" scenario where medication effects combine with underlying diabetic complications

• Each additional day since the last GLP-1 dose reduced the risk by 23%, suggesting timing matters for medical procedures